Why the study?
Enterovirus A71 poses a threat to children under five years old, but there are still no effective antivirals for treatment.
This review highlights the successful clinical development of inactivated whole EV-A71 vaccines and the ongoing preclinical research into targeted antiviral therapies.
No immediate practice change for HFMD is warranted; leaves open real-world vaccine effectiveness and antiviral clinical development.
Enterovirus A71 (EV-A71) is an important emerging virus posing a threat to children under five years old. EV-A71 infection in infants or young children can cause hand-foot-and-mouth disease, herpangina, or severe neurological complications. However, there are still no effective antivirals for treatment of these infections. In this review, we summarize the antiviral compounds developed to date based on various targets of the EV-A71 life cycle. Moreover, development of a vaccine would be the most effective approach to prevent EV-A71 infection. Therefore, we also summarize the development and clinical progress of various candidate EV-A71 vaccines, including inactivated whole virus, recombinant VP1 protein, synthetic peptides, viral-like particles, and live attenuated vaccines.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: